Bintrafusp alfa is a bifunctional fusion protein comprising a human anti–PD-L1 antibody fused to the soluble extracellular domain of TGF-ß receptor II and referred to as a “TGF-ß trap.” This novel therapeutic generated much excitement when preliminary data demonstrated a high objective response rate in PD-L1–high non-small cell lung cancer and other solid tumors (44, 45). This evidence concerns the gene CD274 and non-small cell lung carcinoma.